FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague ...

Men with cirrhosis have a significantly higher risk for liver-related complications ― particularly hepatocellular carcinoma ― ...

Patients with cirrhosis and minimal hepatic encephalopathy often experience sleep difficulties, but treatment with benzodiazepines is frequently ineffective and can have serious side effects ...

Cirrhosis, a chronic liver disease, results from long-term damage and scarring, impairing vital functions. Common causes include alcohol abuse, hepatitis, and fatty liver disease. Early detection ...